Moving beyond the binary: how the convergence of small and large molecules is reshaping pharmaceutical R&D

Pharmaceutical R&D is at an inflection point. Consider that small molecules accounted for 65% of FDA novel drug approvals in 2025. That is a jump from 56% in both 2023 and 2024. The note that even as biologic sales are growing three times faster than their chemical counterparts and are projected to overtake them by… The post Moving beyond the binary: how the convergence of small and large molecules is reshaping pharmaceutical R&D appeared first on Drug Discovery and Development.

Continue reading →